Status:
COMPLETED
Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386
Lead Sponsor:
AstraZeneca
Conditions:
Pain
Eligibility:
MALE
35-50 years
Phase:
PHASE1
Brief Summary
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD1386 in healthy male volunteers.
Eligibility Criteria
Inclusion
- Body Mass Index of 18 - 30 and weight of 50 to 100 kilos.
- Healthy volunteer must have regular bowel movements (at least once daily)
Exclusion
- History of psychiatric or somatic disease/condition, which may interfere with the objectives of the study as judged by the investigator.
- A family history of short QT syndrome or sudden cardiac death amongst first degree relatives.
- Any clinically important abnormalities in heart rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00832169
Start Date
January 1 2009
End Date
February 1 2009
Last Update
April 28 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Macclesfield, CHESHIRE, United Kingdom